

## ***In silico* studies of novel naphthalene hydrazone derivatives as enoyl acyl carrier protein reductase inhibitors**

**Pankaj Gupta<sup>1</sup>, Rakesh Narang<sup>1\*</sup>, Sangeeta Verma<sup>2</sup>, Sukhbir Lal<sup>2</sup>, Somdutt Mujwar<sup>3</sup>, Manish Devgun<sup>2</sup>, Rohit Pal<sup>4</sup> and Gurubasavaraja Swamy Purawarga Matada<sup>1</sup>**

<sup>1</sup>Department of Pharmaceutical Sciences, Gurugram University, Gurugram, Haryana, India

<sup>2</sup>Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra, Haryana, India

<sup>3</sup>Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India

<sup>4</sup>Integrated Drug Discovery Centre, Department of Pharmaceutical Chemistry, Acharya and BM Reddy College of Pharmacy, Bengaluru, Karnataka, India

**ABSTRACT** Tuberculosis (TB), caused by mycobacterial strains, remains a global threat, especially due to multidrug-resistant forms. Enoyl acyl carrier protein reductase (InhA) mutations contribute to resistance in 20–25% of clinical isolates, highlighting the need for novel inhibitors. The present study involves *in silico* analysis of eighty-one naphthalene-based hydrazone derivatives against InhA (PDB ID: 2X22). Compounds **78** and **79** showed strong binding affinities (–11.61 to –11.69 kcal/mol) as compared to the reference drug Isoniazid (binding energy = –5.28 kcal/mol) and favorable pharmacokinetic profiles. Compound **78** has shown high thermodynamic stability throughout 100 ns MD simulation without any major fluctuation, while DFT analysis confirmed the electronic stability of compounds **78** and **79** ( $\Delta E = 0.159$  eV and 0.149 eV, respectively). Therefore, compounds **78** and **79** may act as lead molecules in the development of potent antitubercular agents for the successful clinical management of resistant TB.

**KEYWORDS** Antimycobacterial, Enoyl acyl carrier protein reductase inhibitor, Density functional theory, Molecular docking, Molecular dynamics simulation, 2-Naphthoxyacetic acid hydrazide/hydrazone.

**How to cite this article:** Gupta, P., Narang, R., Verma, S., Lal, S., Mujwar, S., Devgun, M., Pal, R., and Matada, G.S.P. *In silico* studies of novel naphthalene hydrazone derivatives as enoyl acyl carrier protein reductase inhibitors, *Indian J. Heterocycl. Chem.*, **2025**, *35*, 835–843. <https://doi.org/10.59467/IJHC.2025.35.835>